Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ZURA stock, giving a Buy rating on May 9.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Faisal Khurshid’s rating is based on Zura Bio’s strategic advancements and promising developments in their clinical trials. The initiation of the Phase 2 TibuSHIELD trial for tibulizumab in patients with hidradenitis suppurativa (HS) is a significant milestone, demonstrating the company’s timely execution and commitment to advancing its position in the competitive HS landscape. The trial’s design, which includes a randomized placebo-controlled study with a primary assessment period of 16 weeks, aims to provide critical data by the third quarter of 2026.
Additionally, the ongoing Phase 2 TibuSURE trial for systemic sclerosis (SSc) and the anticipated readthrough from Novartis’ ianalumab trial in HS are viewed as relevant catalysts that could potentially de-risk the BAFF hypothesis for tibulizumab. The strong biological rationale for tibulizumab, combined with the company’s strategic positioning amid a crowded competitive field, supports the Buy rating. Management’s clear guidance and the expected data readouts further reinforce confidence in Zura Bio’s potential for growth.
Khurshid covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, aTyr Pharma, and Kymera Therapeutics. According to TipRanks, Khurshid has an average return of 22.7% and a 42.50% success rate on recommended stocks.
In another report released on May 9, Oppenheimer also maintained a Buy rating on the stock with a $17.00 price target.